Federal contract award
36C26125N0101
RADIOACTIVE DRUG INDICATED FOR POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED METASTASIS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | 261-NETWORK CONTRACT OFFICE 21 (36C261) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | 36C26123A0025 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $905.8K |
| Current contract value | $905.8K |
| Potential contract value / ceiling | $905.8K |
| Start date | Oct 1, 2024 |
| Current end date | Sep 30, 2025 |
| Potential end date | Sep 30, 2025 |
| Latest award activity | Dec 19, 2025 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 19, 2025 | P00002 | $36.0K | RADIOACTIVE DRUG INDICATED FOR POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED METASTASIS_INCREASE QUANTITIES |
| Sep 15, 2025 | P00001 | $126.4K | RADIOACTIVE DRUG INDICATED FOR POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED METASTASIS_INCREASE QUANTITIES |
| Oct 1, 2024 | 0 | $743.4K | RADIOACTIVE DRUG INDICATED FOR POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED METASTASIS |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.